Literature DB >> 18415177

[Sustained-release dextropropoxyphene.].

K Kurz-Müller1, M Zenz.   

Abstract

Dextropropoxyphene is a mild opioid analgesic whose analgesic potency corresponds to that of acetylsalicylic acid and paracetamol. It has a similar analgesic effect to codeine but also a considerably lower addiction and dependence potential. Dextropropoxyphene is a therapeutic alternative to other weak opioids such as codeine or dihydrocodeine. In the case of absolute intolerance of non-steroidal anti-inflammatory agents, their analgesic effect can be replaced by that of dextropropoxyphene. In case of relative intolerance, i.e. occurrence of non-tolerable side-effects, the dose of non-steroidal anti-inflammatory agents can be kept low by additional administration of dextropropoxyphene, which simultaneously enhances analgesia. Analgesics are prescribed according to a definite time schedule for the long-term treatment of chronic pain. The oral route of administration is preferred since it enables the patient to be independent of the nursing staff. Sustained-release drugs with a duration of action of at least 8 h are used in preference to other preparations. Sustained-release dextropropoxyphene provides analgesia for 8-12 h. Sustained-release dextropropoxyphene clearly differs from non-sustained-release dextropropoxyphene in its pharmacokinetics. Repeated administration of the sustained-release form at the therapeutically recommended intervals does not lead to cumulation, and the risk of accidental overdosage is extremely low. Intoxication can only occur after simultaneous ingestion of alcohol or other centrally depressant substances or in the presence of hepatic and/or renal failure. Sustained-release dextropropoxyphene is a sensible and undeniable alternative for the second stage in the analgesic ladder of chronic pain therapy.

Entities:  

Year:  1991        PMID: 18415177     DOI: 10.1007/BF02527803

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  84 in total

1.  The pharmacologic effects of a new analgesic alpha-4-dimethylamino-1,2-diphenyl-3-methyl-4-propionyloxybutane.

Authors:  E B ROBBINS
Journal:  J Am Pharm Assoc Am Pharm Assoc       Date:  1955-08

2.  Neonatal drug withdrawal from propoxyphene.

Authors:  W W Quillian; C A Dunn
Journal:  JAMA       Date:  1976-05-10       Impact factor: 56.272

Review 3.  Analgesic efficacy of dextropropoxyphene and dextropropoxyphene-containing combinations: a review.

Authors:  W T Beaver
Journal:  Hum Toxicol       Date:  1984-08

Review 4.  [Opiate receptors].

Authors:  L Latasch; R Christ
Journal:  Anaesthesist       Date:  1986-02       Impact factor: 1.041

5.  Acute propoxyphene self-poisoning in 222 consecutive patients.

Authors:  P Sloth Madsen; J Strøm; S Reiz; M Bredgaard Sørensen
Journal:  Acta Anaesthesiol Scand       Date:  1984-12       Impact factor: 2.105

6.  Cardiovascular function measured by ultrasound Doppler in healthy young men after ingestion of dextropropoxyphene napsylat.

Authors:  T Lang-Jensen; B Thisted; T Krantz; M B Sørensen; E Jacobsen; H R Angelo
Journal:  Pharmacol Toxicol       Date:  1989-02

7.  Comparison of diflunisal and dextropropoxyphene napsylate in the treatment of post-operative pain.

Authors:  P Jalovaara; H Kiviniemi; M Ståhlberg
Journal:  Ann Chir Gynaecol       Date:  1985

8.  The effectiveness and side-effect liability of propoxyphene hydrochloride and propoxyphene napsylate in patients with postpartum uterine cramping.

Authors:  A Baptisti; C M Gruber; E L Santos
Journal:  Toxicol Appl Pharmacol       Date:  1971-07       Impact factor: 4.219

9.  Self-poisoning with dextropropoxyphene and dextropropoxyphene compounds: the USA experience.

Authors:  B S Finkle
Journal:  Hum Toxicol       Date:  1984-08

Review 10.  Impact of non-narcotic oral analgesics on pain management.

Authors:  W T Beaver
Journal:  Am J Med       Date:  1988-05-20       Impact factor: 4.965

View more
  1 in total

1.  [WHO step II-clinical reality or a didactic instrument?].

Authors:  R Freynhagen; M Zenz; M Strumpf
Journal:  Schmerz       Date:  1994-12       Impact factor: 1.107

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.